Details

Published: 30 April 2026

Hits: 100

Scientists in Israel have just engineered a tobacco plant to grow five psychedelic drugs at once. They call it pharmaceutical progress. They call it a simpler, more sustainable route to medicine. Yet what they have actually built, beneath the language of research and therapeutic potential, is a more efficient delivery system for psychotropic compounds that have already demonstrated, repeatedly and on the record, that they harm people. This is where psychedelic drug research has arrived. Not at a cure. At a crop.

The five compounds produced by the modified tobacco plant are psilocybin and psilocin, found in magic mushrooms; DMT, extracted from various plants; and bufotenin and 5-methoxy-DMT, secreted by the Colorado river toad. Using a technique called agroinfiltration, researcher Asaph Aharoni and his team at the Weizmann Institute introduced nine foreign genes into a single tobacco plant and produced all five simultaneously. Furthermore, Aharoni confirmed that the same process could be applied to tomato, potato and corn.

He chose not to make the modification permanent. When asked why, he said it would be “a little bit tricky” because people would ask for seeds.

Read that again. The lead scientist on a project that others present as medical advancement describes his primary reason for restraint as the inconvenience of people asking for seeds. This is not pharmaceutical development. Instead, this is cultivation of some of the most powerful mind-altering substances on earth, with a voluntary handbrake that nobody is required to keep applied.

What the Evidence Actually Says

Before researchers harvest a single tobacco plant, it is worth asking what the therapeutic case for these compounds actually looks like. Because psychedelic drug research has been telling the same story for years: breakthrough treatment, revolutionary potential, the dawn of a new era in mental health. Yet the evidence has never caught up with the narrative.

Notably, the largest comparison trial of psilocybin ever conducted enrolled just 59 people. Earlier studies ran on 12 to 27 participants, some with no control group at all. These are not the foundations of proven medicine. Rather, they are the foundations of a billion-dollar industry that decided momentum was more important than proof.

The conflicts of interest run deep. One leading psychedelic drug researcher acknowledged knowing only a single colleague who had never personally used the drugs being studied. Moreover, financial ties between researchers and the psychedelic companies funding them appear disclosed in paper after paper. The field has a term for this kind of research: “me-search.” Research that finds what it was always going to find because the people running it already believe the answer.

Although the surge of investment and media attention surrounding psychedelic-assisted therapy has been enormous, the quality of the science has not kept pace. Growing scepticism has been building within the scientific community itself, not from outside critics, but from researchers who have looked closely at the evidence and found it wanting. It has simply attracted more investment and more media attention.

The Brain Studies Say “Shaky Ground”

In April 2026, researchers published the most comprehensive study of psychedelic drugs and the brain ever conducted in Nature Medicine. The study drew on more than 500 brain scans, 267 participants, eleven independent studies, and five substances, including three of the five now grown in an Israeli greenhouse. Researchers found that all five flatten the brain’s natural processing hierarchy, dissolving the organised structure through which the brain normally functions and producing what they called “unleashed cross-talk between brain systems.”

Journalists widely reported this as a landmark finding. However, what received far less coverage was what the study’s senior author said about the state of his own field: “This field is emerging, and it is very important, but they are on shaky ground.”

Additionally, the study’s own rigorous modelling found that earlier, smaller studies claiming widespread brain disintegration under psychedelics did not hold up. For context, the DMT dataset, covering one of the five compounds now cultivated in that tobacco plant, comprised only 16 participants. The ayahuasca dataset comprised just nine. Yet these are the numbers researchers use to justify scaling production.

Shaky ground is not a metaphor here. It is the senior researcher’s own description. Consequently, the response from the laboratory is to build a greenhouse.

The Placebo Problem Nobody Wants to Name

A fundamental flaw sits at the heart of psychedelic-assisted therapy trials that the industry does not advertise. Researchers cannot blind these studies. Participants always know whether they have taken a psychedelic drug, because the effects are unmistakable. As a result, every trial result carries contamination by expectation. People who believe they receive a powerful treatment often feel better simply because they believe it. People who realise they received a placebo sometimes deteriorate sharply from the disappointment.

Researchers at the University of Auckland and King’s College London have both published work on this problem. Their conclusion is stark: the large differences between treatment and placebo groups in psychedelic drug research trials likely measure more than just improvement in the treated group. In fact, they also measure deterioration in the placebo group. Consequently, the results are inflated, and the industry is overstating the effectiveness of these drugs. Meanwhile, the tobacco plant is being engineered to grow more of them.

The People Nobody Mentions

Behind all the trial data and the brain scans and the greenhouse engineering, there are people. They tend not to appear in the press releases.

Kate Hyatt was 32 years old. In June 2021 she attended a plant medicine retreat in Worcestershire and took a powerful hallucinogen. Three months later she described a psychotic break so severe she felt her brain was going to explode. That autumn she took her own life. The coroner linked her deteriorating symptoms to the hallucinogens she had consumed. She had gone looking for help with her mental health. The psychedelic-assisted therapy movement gave her something that destroyed it.

She is not alone. A Compass Pathways clinical trial of psilocybin for treatment-resistant depression reported that three participants showed suicidal behaviour lasting at least a month after receiving the drug. Furthermore, a 21-year-old woman who self-medicated with a high dose of psilocybin to treat her own depression walked to the middle of the Golden Gate Bridge and jumped. In MAPS-sponsored MDMA therapy trials, footage emerged of therapists restraining a patient, gagging her and lying on top of her while she was under the influence of the compound. The lead therapist later admitted to having sex with her while she remained enrolled in the trial.

These are not aberrations. Rather, they are the logical consequence of administering compounds that, by the admission of researchers in the field, make users “pliant and suggestible.” When a substance dissolves the brain’s normal defences and places a vulnerable person in the hands of anyone with less-than-honourable intentions, the outcome is not always therapeutic. Sometimes it is devastating. No tobacco plant, however efficiently engineered, changes that pharmacological reality.

Science Racing Ahead of Ethical Reckoning

There is a word for what happens when scientific capability races ahead of ethical reckoning. The Weizmann Institute has demonstrated that five psychotropic compounds can grow in a single crop, at agricultural scale, using a process transferable to the most common food plants on earth. They have done this in a field where the therapeutic evidence sits on shaky ground by the admission of its own senior researchers, where documented harms include deaths, suicidal behaviour within clinical trials and sexual abuse within supervised therapy sessions, and where a scientist’s reluctance to deal with seed requests stands as the primary restraint against open distribution.

The creature, to borrow Mary Shelley’s framing, is not being built because medicine needs it. Instead, the laboratory builds it because the capital is there, and because a field that has never allowed evidence to slow its momentum now has a cultivation method that grows in soil, requires no pharmaceutical supply chain and can scale without limit.

Rupert Fray at the University of Nottingham called it a valuable technical accomplishment and spoke of “green factories” growing compounds in greenhouses. He is right about the factories. However, the question his framing avoids is what these factories are actually producing, and for whom.

This Is Not Medicine. This Is Access.

Psychedelic drug research has not yet established what these compounds treat, in whom they are safe, at what dose, under what supervision or with what long-term consequences. Its own most rigorous brain study describes its foundations as shaky. Its own researchers acknowledge the conflicts of interest. Moreover, its own clinical trials have produced documented suicidal behaviour and enabled abuse.

What it has established, reliably and at scale, is an appetite. An appetite in an industry, in a media cycle and in a culture that has decided these substances are the next frontier, and that the science can catch up later. Therefore, the tobacco plant is not the beginning of responsible pharmaceutical development. It is the next step in a process that has never been primarily about medicine.

The lead researcher noted that people will ask for seeds. He is correct. They will. And when they do, the question of whether psychedelic drug research ever delivered on its therapeutic promise will feel very distant from the reality of what was grown, and where it ended up.

(Source: WRD News)

Details

Published: 18 April 2026

Hits: 59

A landmark study published in the journal Brain has confirmed that regular ‘recreational’ use of MDMA, commonly known as ecstasy, causes measurable MDMA brain damage. Scientists found that the drug shrinks key memory regions and that the damage worsens the more a person uses it.

The research involved 122 participants across the University of Zurich. It is among the most thorough investigations to date into what ecstasy does to the human brain structurally. Its findings paint a sobering picture for anyone who considers recreational use low risk.

What the Study Found About MDMA Brain Damage

Researchers compared 61 regular MDMA users with 61 matched controls who had never used the drug. Each participant had detailed MRI brain scans and completed a series of verbal memory tests.

The results were striking. MDMA users had significantly reduced grey matter volume in the hippocampus, the brain’s primary hub for forming and storing memories. The loss centred on the CA1 and CA2/3 subregions, which are critical for verbal learning and long-term recall.

The memory test scores told the same story. MDMA users performed notably worse across four key measures:

• Learning performance scored significantly lower
• Recall after interference showed a marked decline
• Long-term delayed recall dropped considerably
• Recognition accuracy fell well below the control group

Only supraspan, a measure of immediate memory capacity, showed no significant difference between the two groups.

The More You Use, the Worse the Ecstasy Memory Loss

One of the study’s most valuable contributions was linking the extent of brain damage directly to consumption levels. Researchers used hair toxicology tests, which provide an objective record of drug intake over the previous three to four months. They found a clear pattern: the higher the MDMA concentration in a person’s hair, the smaller their hippocampal CA1 volume.

Self-reported MDMA use in the previous six months also predicted worse scores across learning, interference recall and long-term recall. No other substance in the study produced the same pattern. Alcohol, cannabis, cocaine and amphetamine all came up short, even though MDMA users consumed more of those substances than controls did.

That dose-response relationship is significant. It strongly suggests the cognitive deficits stem from MDMA specifically, not from general drug use. The evidence points squarely at ecstasy.

A Serotonin System Under Attack

MDMA brain damage does not strike at random. The study correlated the regions of structural brain change with published brain maps showing where serotonin receptors concentrate most densely.

The pattern held up consistently. The brain regions showing the greatest grey matter loss in MDMA users were the same regions richest in 5-HT1A, 5-HT2A and 5-HT4 serotonin receptors.

This finding matters because MDMA works by flooding the brain with serotonin. That flood produces the drug’s well-known feelings of euphoria and warmth in the short term. Over time, however, it appears to degrade the serotonergic architecture of the brain, especially in receptor-dense areas.

The study authors noted that grey matter differences between groups aligned closely with 5-HT1A, 5-HT2A and 5-HT4 receptor density maps, pointing to a serotonergic basis for both the memory problems and the structural changes.

One finding stood out. The serotonin transporter (SERT), a long-studied marker in ecstasy memory loss research, did not correlate with grey matter changes here. Other research has shown SERT levels can recover with abstinence while memory deficits remain. That suggests something more permanent may be happening at a structural level.

Why MDMA Brain Damage Matters Beyond the Lab

The hippocampus is not just another brain region. It sits at the centre of our ability to learn new information, navigate our surroundings and recall life events. Doctors associate shrinkage in this area with depression, Alzheimer’s disease and post-traumatic stress disorder.

This is not about extreme or clinical drug use. The MDMA users in this study were recreational users, the kind who take ecstasy at weekends in clubs and at festivals. Yet their hippocampal volumes shrank to a statistically and clinically meaningful degree.

The scale of the problem is worth noting. According to the European Drug Report 2024, ecstasy remains popular across Europe, particularly among young adults aged 15 to 34. In the UK, surveys consistently place it among the top five most widely used recreational drugs. A separate prospective study found that even low cumulative MDMA use produced verbal memory declines in previously drug-naive individuals, with deterioration measurable within 12 months of first use.

Limitations and What Comes Next

The study’s cross-sectional design means researchers captured a single point in time rather than tracking individuals before and after MDMA use began. They could not fully rule out pre-existing differences between groups, though the careful matching process and dose-response findings make that explanation less convincing.

MDMA users also consumed more alcohol, tobacco and cannabis than controls. The researchers controlled for those factors statistically and confirmed that stimulant co-use did not account for the grey matter findings.

The team used population-level serotonin receptor atlases rather than individual PET scans. That approach has broad acceptance in the field but does limit what researchers can say about any single person’s brain chemistry.

A longitudinal study tracking brain structure over time in new MDMA users would be the logical and powerful next step.

The Takeaway on Ecstasy Memory Loss

The evidence keeps pointing in the same direction. Ecstasy memory loss is not a myth, an exaggeration or a side effect of polydrug use. It is a measurable, dose-dependent consequence of taking MDMA, one that roots itself in the drug’s disruption of the serotonin system and its lasting impact on brain structure.

For anyone weighing the risks of recreational use, the neuroscience is increasingly difficult to dismiss. The MDMA brain damage these scans reveal is real. It scales with how much you take. And it targets the very regions the brain relies on to learn, remember and function each day.

(Source: WRD News (Brain))

Details

Published: 08 April 2026

Hits: 143

A major scientific review has concluded that e-cigarettes are likely to cause cancer. The finding could reshape how governments, health bodies and the public think about vaping. Published in the journal Carcinogenesis on 31 March 2026, the study offers one of the most comprehensive assessments of the e-cigarette cancer risk to date. It raises serious questions about a product long marketed as a safer alternative to smoking.

What the Review Found About E-Cigarette Cancer Risk

Professor Bernard Stewart, a cancer researcher at the University of New South Wales (UNSW) in Sydney, led the review. His team examined a wide body of evidence including clinical data, animal studies and laboratory experiments. The central finding was stark: nicotine-based vapes are “likely to be carcinogenic to humans.”

“Considering all the findings, from clinical monitoring, animal studies and mechanistic data, e-cigarettes are likely to cause lung cancer and oral cancer,” Professor Stewart said during a media briefing.

Many previous studies evaluated vaping only by comparing it with cigarette smoking. This review assessed the e-cigarette cancer risk on its own terms. That distinction matters. For years, the harm reduction argument has driven public health policy on vaping. This research challenges that framing directly.

The Science Linking Vaping and Cancer

E-cigarettes have only been in widespread use for around 20 years. Long-term population studies simply do not exist yet. Rather than waiting decades for that data, researchers examined biomarkers, the early biological changes that signal cancer development.

Studies in the review show that people who vape absorb nicotine-related compounds, heavy metals and other chemicals. These substances damage DNA and trigger inflammation, both of which drive cancer.

Animal studies add further weight to the concern. In one experiment, mice exposed to e-cigarette aerosols developed lung tumours at significantly higher rates than control groups. They also showed bladder changes linked to cancer.

“There is no doubt that the cells and tissues of the oral cavity and the lungs are altered by inhalation from e-cigarettes,” Professor Stewart said.

Dual Use Is Compounding the Vaping and Cancer Threat

Researchers call it “dual use.” It describes the pattern where people use both e-cigarettes and traditional cigarettes rather than fully switching. More than half of users studied could not quit either habit.

Co-author Professor Freddy Sitas, an epidemiologist at UNSW, highlighted data from the United States. People who both vape and smoke face a fourfold increased risk of developing lung cancer compared with those who do neither.

The global vaping industry is worth an estimated $30 billion to $46 billion. Major tobacco companies including Altria Group, British American Tobacco and Imperial Brands have invested heavily in e-cigarettes. For those companies, these findings carry significant commercial and regulatory weight.

A Warning From History

The review draws an uncomfortable parallel with the history of tobacco research. Scientists took decades to prove conclusively that cigarette smoking causes lung cancer. Early warning signs existed long before the field reached consensus. The authors argue researchers should not repeat this mistake with vaping and cancer.

“We should not wait another 80 years to decide what to do,” Professor Sitas said.

The concern grows sharper given how quickly vaping has spread among young people. A generation is now growing up with the habit. The long-term consequences remain unknown.

What E-Cigarette Cancer Risk Means for Public Health

Countries including New Zealand and the United Kingdom have actively encouraged smokers to switch to vaping. The new analysis questions whether those approaches adequately account for the long-term vaping and cancer relationship.

Health experts involved in the study were clear on one point. Their findings should not push smokers back to cigarettes, which remain far more harmful.

“We have always assumed that vapes are safer than cigarettes, but what we are showing is that they might not be safe after all,” Professor Sitas said.

The assessment remains qualitative. Researchers have not yet produced a numerical estimate of cancer risk. Even so, reviews over the past decade have moved steadily from uncertainty toward serious concern about carcinogenic effects.

The Bottom Line

The e-cigarette cancer risk is real, even if scientists cannot yet put a precise number on it. The idea that vaping carries no meaningful health consequences has always rested more on a lack of evidence than on proof of safety.

This review brings the long-term consequences of vaping into sharper focus. Governments, regulators and individuals now face a clear question. Act on the evidence now, or wait for certainty that may arrive too late.

(Source: WRD News)

Details

Published: 01 April 2026

Hits: 75

A veterinary sedative used to tranquillise elephants is now showing up in the illegal drug supply across New York State. Authorities warn the medetomidine overdose crisis is more dangerous than anything they have seen in recent years. Dealers quietly mix this powerful animal sedative into opioid supplies without users’ knowledge, triggering a surge in deaths and life-threatening withdrawal episodes.

What Is Medetomidine and Why Is It Fuelling Overdose Deaths?

Most people have never heard of medetomidine. Veterinarians use it to sedate large animals, including elephants. Over the past two years, it has entered the illicit drug market at a pace that alarms toxicologists, paramedics, and prosecutors alike.

Assistant District Attorney Matthew Gamberg is deputy chief of the Narcotics-Investigations Bureau in Staten Island. He told the Staten Island Fentanyl and Overdose Task Force in March 2025 that medetomidine is 200 to 300 times more potent than xylazine. Xylazine is another veterinary drug previously linked to overdose deaths and disability.

“Xylazine is still prevalent in the drug supply, but its presence is definitely on a downward trend,” Gamberg said. “It is being replaced with medetomidine, which, for all intents and purposes, is worse.”

Dealers add the drug to fentanyl to extend its effects. Fentanyl wears off in roughly half the time heroin does. So dealers blend in medetomidine and xylazine to prolong the high. That combination carries lethal consequences for unsuspecting users.

How Fast Is the Medetomidine Overdose Crisis Spreading?

The numbers tell a troubling story. New York State Drug Checking Programmes first spotted medetomidine in a sample in May 2024. Just four months later, it turned up in over 23% of opioid samples tested.

By October 2025, that figure reached 37% of all opioid samples. During the same period, xylazine appeared in 40% of opioid samples. Two potent veterinary sedatives now circulate simultaneously in the street supply.

The New York State Department of Health issued a public health alert in December, citing life-threatening side effects and the rapid spread of medetomidine across the state’s drug market.

It Makes Naloxone Less Effective

One of the most frightening parts of the medetomidine overdose crisis is how it undermines naloxone, the most widely used overdose reversal tool available (commonly known as Narcan).

Medetomidine is not an opioid. Naloxone does not fully reverse its effects. Emergency responders may administer naloxone and revive a patient from opioid-related respiratory depression. Yet the person can remain deeply sedated because the medetomidine component stays active.

This gap complicates emergency care significantly. Communities relying on naloxone as a first-line response now work with an incomplete tool. In cases involving veterinary drug overdose deaths linked to medetomidine, that gap can cost lives.

Withdrawal from Medetomidine Can Kill

The dangers do not end with the overdose itself. The New York City Department of Health and Mental Hygiene warns that medetomidine withdrawal can require intensive medical care and hospitalisation.

Emergency room visits for medetomidine withdrawal rose sharply last year. Opioid withdrawal is deeply unpleasant but rarely fatal for otherwise healthy adults. Medetomidine withdrawal is different. It disrupts the cardiovascular system and can cause blood pressure to drop, heart rate to slow, and breathing to suppress.

Health officials urge anyone withdrawing from drugs that may contain medetomidine to seek immediate medical attention. Trying to manage those symptoms at home puts lives at serious risk.

Fake Anti-Anxiety Pills Add to the Medetomidine Overdose Crisis

Medetomidine is not the only new danger circulating in the illicit market. In March 2026, the US Drug Enforcement Administration (DEA) issued a nationwide alert about bromazolam. This synthetic benzodiazepine now appears in counterfeit prescription pills designed to look like anti-anxiety medications such as alprazolam (Xanax).

The DEA elevated bromazolam to the top tier of the controlled substances schedule on an emergency basis through March 2028. Trafficking has increased and the drug carries no accepted medical use and a high potential for abuse.

Manufacturers frequently mix bromazolam with fentanyl. Counterfeit pills are notoriously difficult to tell apart from legitimate ones by sight alone. The DEA has repeatedly warned that fake prescription pills can contain fatal doses of fentanyl.

Bromazolam causes slurred speech, loss of bodily coordination, altered mental state, and respiratory depression.

Cocaine Rises as Fentanyl Trends Down Slightly

There is a partial bright spot in the data. Fentanyl remains the leading driver of overdose deaths, but its potency and prevalence show some decline on Staten Island. Gamberg says law enforcement officers in the borough now recover less fentanyl and more cocaine.

Cocaine’s rise carries its own risks. It rarely kills on its own, but it frequently appears alongside fentanyl in fatal overdose toxicology reports. The United Nations World Drug Report 2025 found that global cocaine production reached an all-time high, with significant increases in seizures, users, and cocaine-related deaths across many countries.

Nearly every drug law enforcement recovers on the island, except cocaine, tests positive for multiple substances. Heroin almost always combines with fentanyl, medetomidine, xylazine, and lidocaine. A single sample can contain over 20 different substances. That complexity makes overdose reversal far harder.

Overdose Deaths Are Falling, but the Veterinary Drug Overdose Deaths Toll Remains Too High

Staten Island has made real progress. Overdose deaths in the borough fell by nearly 50% in 2024. Preliminary figures suggest that downward trend continued through 2025 and into 2026.

But District Attorney Michael E. McMahon was clear: the numbers remain unacceptably high. He hosted the March task force meeting and cautioned that the spread of medetomidine, bromazolam, and increasingly complex drug combinations demands that response strategies keep evolving.

Communities, healthcare providers, and policymakers must stay current on the medetomidine overdose crisis. Early detection, stronger withdrawal treatment protocols, and broader public awareness are not optional. For anyone struggling with substance use, or for those who love someone who is, knowing what is in the supply chain today can be a matter of life and death.

(Source: WRD News)